Table of Content

Table of Contents
i. Antimicrobial Resitance - Strategic Situation Analysi.......19
i. Guide for Executives, Marketing, Sales and Busines Development Staf.......................................23
i. Guide for Management Consultants and Investment Advisors..25

1. Introduction and Market Definiton ..................26
1.1 The Growing Threat and Opportunity of Antimicrobial Resitance.27
1.2 Defining the Opportunity ........................30
1.2.1 Revenue Market Size.........................30
1.3 Methods and Sources..........................31
1.3.1 Authors.................................31
1.3.2 Sources.................................32
1.4 U.S. Antibiotic Markets - Perspective ..................3
1.4.1 U.S. Outpatient Use of Antibiotics..................34
1.4.2 U.S. Pharmaceutical Spending...................38

2. Overview of a Dynamic Market....................42
2.1 Market Players – Roles & Impacts....................43
2.1.1 Drug manufacturers - Larger/pharmaceutical...........4
2.1.2 Drug manufacturers - Generic....................46
2.1.3 Contract Research and Manufacturing ..............46
2.1.4 In Vitro Diagnostics Industry.....................47
2.1.5 Drug Marketing Companies.....................49
2.1.6 Biotechnology Companies .....................49
2.1.7 Regulatory Bodies...........................50
2.2 Understanding Antimicrobial Resitance ................52
2.2.1 What is Antimicrobial Resitance (AMR)..............53
2.2.2 Bacteria and Other Microbes....................54
2.2.3 The History of Antibiotics .......................62
2.2.4 The Role of Animal Husbandry....................67
2.2.5 The Implications of Horizontal Transfer ...............69
2.2.6 The Threat of AMR...........................71
2.3 The Changing Road to New Antibiotics & Technologies.......74
2.4 The Key Role of Diagnostics in AMR...................7

3. The Market Opportunity of AMR ...................79
3.1 The Key Large Market Opportunites in AMR ..............80
3.1.1 Streptococcus Pneumoniae (DRSP).................81
3.1.2 Campylobacter (DRC) ........................85
3.1.3 Clostridium Dificile (CD).......................89
3.1.4 Staphylococcus aureus (MRSA) ...................93
3.1.5 Neiseria gonorhoeae (DRNG) ...................97
3.1.6 Salmonela (DRNTS) .........................101
3.2 Therapeutic Technology Development Opportunites .......105
3.2.1 Using Viruses Against Bacteria ...................107
3.2.2 Hydrolytic Enzymes Join the Fight..................109
3.2.3 Antibodies...............................11
3.2.4 Vaccines...............................15
3.2.5 Probiotic Technology ........................16
3.2.6 Peptides vs. Pathogens.......................17
3.2.7 Mining Obsolete Science ......................18
3.2.8 CRISPR Antibiotics..........................18
3.3. Antibiotic Resitance Recent Developments............120
3.3.1 Recent Developments – Importance and How to Use This Section........................................120
3.3.2 Importance of These Developments ...............120
3.3.3 How to Use This Section.......................120
New clas of antibiotics for AMR.....................120
New AMR Drug...............................123
CRISPR Modifes Phages to target Superbugs .............124
Geneticaly Modifed Phage Fights 'Superbug' Infection.......125
NIH awards $3 milion grant to develop new antibiotics.......127
Bacteria found in ancient Irish soil halts growth of superbugs.....128
OpGen Partners With NYS DOH, Merck Subsidiary for AMR Surveilance........................................129
New breakthrough in the war against antibiotic resitance......132
Amicrobe, Inc., patents AMR Gel....................134
Microneedle Patch to Combat AMR..................135
Antimicrobial peptides find application medium ...........136
Antibiotic shortages fueling antimicrobial resitance .........137

4. Key Biotechnology Companies and Their Technology ......140
4.2 Therapeutics...............................140
4.2.1 The Medicines Company ......................141
4.2.2 Melinta Therapeutics........................143
4.2.3 Arsanis ................................145
4.2.4 Phage Technologies S.A ......................147
4.2.5 Westway Health...........................149
4.2.6 Tetraphase Pharmaceuticals....................151
4.2.7 BioVersys GmbH...........................153
4.2.8 Nabriva Therapeutics........................15
4.2.9 Macrolide Pharmaceuticals....................157
4.2.10 Nemesi Bioscience........................159
4.2.1 C3J Therapeutics, Inc........................161
4.2.12 EpiBiome ..............................163
4.2.13 discuva...............................165
4.2.14 SmartPhage.............................168
4.2.15 AmpliPhi Biosciences........................169
4.2.16 Pherecydes Pharma........................171
4.2.17 Micreos...............................172
4.2.18 Procarta Biosystems........................175
4.2.19 Lumavita ..............................178
4.2.20 Madam Therapeutics.......................180
4.2.21 Priaxon................................182
4.2.2 Biolytx Pharmaceuticals......................183
4.2.23 AntibioTx...............................185
4.2.24 Xelia Pharmaceuticals ......................187
4.2.25 Paratek Pharmaceuticals.....................189
4.2.26 Synereca Pharmaceuticals....................191
4.2.27 Alecra Therapeutics ........................193
4.2.28 Fixed Phage.............................195
4.2.29 Enanta Pharmaceuticals, Inc...................197
4.2.30 Demuris ...............................19
4.2.31 Prommune .............................201
4.2.32 Biosergen ..............................202
4.2.3 Innovation Pharmaceuticals...................204
4.2.34 Aviragen Therapeutics.......................205
4.2.35 Achilion Pharmaceuticals.....................207
4.2.36 ImmunNovative Developments, S.L................209
4.2.37 Achaogen, Inc...........................210
4.2.38 SelectX Pharmaceuticals, Inc...................212
4.2.39 TaiGen Biotechnology Co., Ltd..................214
4.2.40 Theravance Biopharma......................215
4.2.41 Abbvie................................218
4.2.42 KYORIN Pharmaceutical Co.,Ltd.................21
4.2.43 Iterum Therapeutics Limited....................23
4.2.4 Forge Therapeutics.........................25
4.2.45 Alopex Vaccine LC.......................27
4.2.46 Integrated Biotherapeutics ....................29
4.2.47 Hennepin Life Sciences......................231
4.2.48 Fedora Pharmaceuticals Inc...................23
4.2.49 Contrafect Corporation .....................235
4.2.50 Basilea Pharmaceutica Ltd....................237
4.2.51 AiCuris................................240
4.2.52 RedHil Biopharma .........................242
4.2.53 Redx Pharma Plc/ Redx Anti Infectives Ltd............245
4.2.54 ABAC Therapeutics ........................247
4.2.5 Alaxia SAS ..............................248
4.2.56 Antabio S.A.S............................250
4.2.57 Auspherix Ltd............................252
4.2.58 BioFilm Pharma...........................254
4.2.59 Centauri Therapeutics Ltd .....................255
4.2.60 Combioxin SA............................257
4.2.61 Da Voltera .............................259
4.2.62 Debiopharm International SA ...................261
4.2.63 Deinobiotics/Deinove .......................263
4.2.64 Destiny Pharma plc ........................264
4.2.65 Eligo Bioscience ..........................267
4.2.6 Helperby Therapeutics Ltd ....................268
4.2.67 Karveel Pharmaceuticals .....................271
4.2.68 MaaT Pharma............................272
4.2.69 Motif BioSciences, Inc / Motif Bio PLC..............274
4.2.70 Mutabils SAS............................27
4.2.71 Neem Biotech Ltd.........................280
4.2.72 Northern Antibiotics Oy (Ltd)...................281
4.2.73 Nosopharm.............................283
4.2.74 NovaBiotics Ltd ...........................285
4.2.75 Phico Therapeutics Ltd.......................287
4.2.76 Polyphor Ltd.............................290
4.2.7 QureTech Bio AB ..........................292
4.2.78 SetLance srl.............................294
4.2.79 Ultupharma AB...........................295
4.2.80 Vaxdyn...............................297
4.2.81 Vibiosphen.............................298
4.2.82 Bioaster...............................30
4.2.83 Vivexia................................301
4.2.85 KBP Biosciences...........................303
4.2.86 Absynth Biologics..........................304
4.2.87 Spero Therapeutics.........................306
4.2.8 Merck ................................307
4.2.89 Symphogen .............................310
4.2.90 Warp Drive Bio...........................31
4.2.91 Johnson & Johnson (Jansen)...................314
4.2.92 Pfizer .................................317
4.2.93 Alergan...............................320
4.2.95 Novartis ...............................324
4.2.97 AstraZeneca............................329
4.2.10 Cipla................................36
4.2.101 DSM Sinochem Pharmaceuticals ................38
4.2.102 Wockhardt Ltd...........................340
4.2.103 VenatoRx Pharmaceuticals ...................342
4.2.104 MicuRx...............................345
4.2.81 Vibiosphen.............................298
4.2.82 Bioaster...............................30
4.2.83 Vivexia................................301
4.2.85 KBP Biosciences...........................303
4.2.86 Absynth Biologics..........................304
4.2.87 Spero Therapeutics.........................306
4.2.8 Merck ................................307
4.2.89 Symphogen .............................310
4.2.90 Warp Drive Bio...........................31
4.2.91 Johnson & Johnson (Jansen)...................314
4.2.92 Pfizer .................................317
4.2.93 Alergan...............................320
4.2.95 Novartis ...............................324
4.2.97 AstraZeneca............................329
4.2.10 Cipla................................36
4.2.101 DSM Sinochem Pharmaceuticals ................38
4.2.102 Wockhardt Ltd...........................340
4.2.103 VenatoRx Pharmaceuticals ...................342
4.2.104 MicuRx...............................345
8.2 Phage Market..............................386
8.3 Pep/Lys Market.............................38
8.4 Antibodies Market............................390
8.5 Vaccine Market.............................392
8.6 Other Technology Market.......................394

9. The Future of AMR...........................396
Appendices...............................398
I. United States Medicare System: Top Seling Drugs 201-2015.....398
 

Table of Tables
Table 1 USA - Outpatient Use of Antibiotics by Clas............35
Table 2 USA - Outpatient Use of Antibiotics Top 5 ..............36
Table 3 Market Players by Type........................43
Table 4 Known Human Pathogenic Diseases................57
Table 5 The Key Market Opportunites ....................80
Table 6 - Market Potential DRSP Therapeutic................83
Table of Tables
Table 1 USA - Outpatient Use of Antibiotics by Clas............35
Table 2 USA - Outpatient Use of Antibiotics Top 5 ..............36
Table 3 Market Players by Type........................43
Table 4 Known Human Pathogenic Diseases................57
Table 5 The Key Market Opportunites ....................80
Table 6 - Market Potential DRSP Therapeutic................83
Table 7 - Market Potential DRC Therapeutic.................87
Table 8 Eight Technologies under development..............105
Table 9 Antibodies Approved for Infectious Disease Treatment .....11
Table 10 Therapeutic Technology Research - # of Companies.....354
TABLE 1 GLOBAL MARKET BY COUNTRY ......................356
TABLE 12 GLOBAL MARKET BY PATHOGEN .....................358
TABLE 13 GLOBAL MARKET BY TECHNOLOGY....................363
TABLE 14 DRSP SEGMENT BY COUNTRY.......................369
TABLE 15 DRC SEGMENT BY COUNTRY.......................371
TABLE 16 CD SEGMENT BY COUNTRY ........................373
TABLE 17 MRSA SEGMENT BY COUNTRY......................375
TABLE 18 DRNG SEGMENT BY COUNTRY ......................37
TABLE 19 DRNTS SEGMENT BY COUNTRY......................379
TABLE 20 OTHER PATHOGEN SEGMENT BY COUNTRY .................381
TABLE 21 ANTIBIOTICS SEGMENT BY COUNTRY....................384
TABLE 2 PHAGE SEGMENT BY COUNTRY......................386
TABLE 23 PEP/LYS SEGMENT BY COUNTRY ......................38
TABLE 24 ANTIBODIES SEGMENT BY COUNTRY ....................390
TABLE 25 VACCINE SEGMENT BY COUNTRY .....................392
TABLE 26 OTHER TECHNOLOGY SEGMENT BY COUNTRY ...............394
Table 27 201 to 2015 Top Seling Drugs...................398


Table of Figures
Figure 1 Pharmaceutical Spending Trends..................39
Figure 2 AMR and Antibiotic Introduction ..................67
Figure 3 The Death Tol of AMR........................72
Figure 4 Phage T4 Anatomy and Infection Cycle .............108
Figure 5 Key Global Markets.........................357
FIGURE 6 PATHOGEN SHARE BY YEAR........................359
FIGURE 7 PATHOGEN SEGMENT GROWTH RATES ...................360
FIGURE 8 SEGMENT SHARE SHIFTS..........................361
Figure 9 Market Share Start Year.......................362
Figure 10 Market Share End Year......................362
FIGURE 1 TECHNOLOGY SHARE BY YEAR......................364
FIGURE 12 PATHOGEN SEGMENT GROWTH RATES ..................365
FIGURE 13 SEGMENT SHARE SHIFTS.........................366
Figure 14 Market Share Start Year......................367
Figure 15 Market Share End Year......................367
FIGURE 16 DRSP VS. TOTAL MARKET GROWTH...................370
FIGURE 17 DRC VS. TOTAL MARKET GROWTH....................372
FIGURE 18 CD VS. TOTAL MARKET GROWTH ....................374
FIGURE 19 MRSA VS. TOTAL MARKET GROWTH...................376
FIGURE 20 DRNG VS. TOTAL MARKET GROWTH...................378
FIGURE 21 DRNTS VS. TOTAL MARKET GROWTH...................380
FIGURE 2 OTHER PATHOGEN VS. TOTAL MARKET GROWTH .............382
FIGURE 23 ANTIBIOTICS VS. TOTAL MARKET GROWTH.................385
FIGURE 24 PHAGE VS. TOTAL MARKET GROWTH ...................387
FIGURE 25 PEP/LYS VS. TOTAL MARKET GROWTH..................389
FIGURE 26 ANTIBODIES VS. TOTAL MARKET GROWTH .................391
FIGURE 27 VACCINE VS. TOTAL MARKET GROWTH ..................393
FIGURE 28 OTHER TECHNOLOGY VS. TOTAL MARKET GROWTH ............395